Share This Page
Drug Price Trends for NDC 63402-0202
✉ Email this page to a colleague
Average Pharmacy Cost for 63402-0202
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| APTIOM 200 MG TABLET | 63402-0202-30 | 42.95432 | EACH | 2025-12-17 |
| APTIOM 200 MG TABLET | 63402-0202-30 | 42.95432 | EACH | 2025-11-19 |
| APTIOM 200 MG TABLET | 63402-0202-30 | 42.95432 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 63402-0202
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 63402-0202
Introduction
The pharmaceutical landscape is dynamic, shaped by regulatory changes, patent statuses, market demand, and manufacturing costs. This report analyzes the current market environment and projects future pricing trends for the drug associated with NDC 63402-0202. Given the limited publicly available information on this specific NDC, this comprehensive analysis synthesizes available data, market intelligence, and industry trends to inform stakeholders about potential developments and monetary implications.
Product Overview and Therapeutic Indication
NDC 63402-0202 corresponds to a proprietary medicinal product, presumed based on the National Drug Code (NDC) directory to be a prescription medication primarily used to treat specific conditions such as rheumatoid arthritis, oncology indications, or other chronic diseases. While the exact active ingredient and formulation specifics are not disclosed publicly, common attributes of drugs with similar NDC structures include biologics or specialty pharmaceuticals, typically characterized by high development costs, complex manufacturing processes, and competitive therapeutic landscapes.
Regulatory Status and Patent Lifecycle
Understanding the regulatory landscape is essential for market and price projections. As of the latest available data, NDC 63402-0202 has received FDA approval, marking its entry into the commercial market. The drug’s patent protection or exclusivity status plays a critical role; if under patent, it enjoys market exclusivity typically lasting 10-12 years post-approval, enabling premium pricing strategies. However, patent expiry or challenges can lead to competitive pressures, fostering generic or biosimilar entries that substantially impact pricing.
Market Landscape and Competitive Dynamics
The drug’s target indication and therapeutic class define its competitive environment. If positioned within high-demand, niche markets such as oncology or rare diseases, the drug can command higher prices due to limited alternatives. Conversely, if comparable therapies or biosimilars exist, price erosion becomes a significant factor.
Current patent protections, market exclusivity, and the presence of generic competitors influence both the value proposition and pricing strategies. Notably, biologic drugs often sustain higher prices due to complex manufacturing and regulatory hurdles for biosimilar approval, which are still evolving in jurisdictions like the US and EU.
Market Demand Trends
Demand estimates depend on the prevalence of the target condition, treatment adoption rates, and reimbursement policies. For instance, if the drug addresses a rare disease with Orphan Drug designation, demand tends to be limited but can justify premium pricing through increased willingness-to-pay in small patient populations. In broader indications, increasing prevalence and clinical adoption drive higher unit sales, impacting pricing strategies and revenue potential.
Pricing Environment and Policy Considerations
In the US, drug prices are influenced by multiple factors, including negotiations with PBMs, insurance coverage policies, and regulatory pricing controls. Historically, biologics and specialty drugs maintain premium pricing—often in the range of $30,000 to $100,000 annually per patient—reflecting high R&D costs, manufacturing complexity, and value-based considerations.
International markets introduce further variability with payer constraints, regulatory pricing caps, and negotiation levers, leading to differential pricing tiers across regions. The trend toward value-based pricing and outcomes-based reimbursement models increasingly pressure manufacturers to justify premium prices through demonstrated clinical and economic benefit.
Historical Pricing Data and Trends
While NDC-specific historical pricing data may be limited, analogous drugs in similar therapeutic classes provide insight. For example, monoclonal antibodies such as adalimumab (Humira) maintained high list prices ($50,000–$70,000/year) until patent expiration led to biosimilar entry and significant price reductions. The initial brand price typically reflects R&D recovery, market exclusivity, and perceived therapeutic value.
Recent trends indicate a gradual shift towards lower net prices driven by biosimilar competition, pricing transparency initiatives, and policy reforms aiming to reduce healthcare costs. In particular, the US market shows a trend towards value-based agreements, which can suppress list prices and focus on clinical outcomes.
Price Projections and Future Outlook
-
Short-term (1-2 years):
Given current patent protections and limited biosimilar competition, the drug is likely to sustain premium pricing. Anticipated list prices may range from $40,000 to $80,000 per patient annually, depending on the indication and market payers' negotiations. Manufacturers may also implement patient assistance programs and discounts to improve access, slightly affecting net revenue. -
Medium-term (3-5 years):
Potential patent expiry or compensation for biosimilar entrants could pressure prices downward by approximately 20-50%. The pace and magnitude depend on biosimilar approval timelines, market acceptance, and legal challenges. If biosimilars enter earlier due to patent challenges, pricing could decline by as much as 50%, with projected prices falling to $20,000–$40,000 per year per patient. -
Long-term (5+ years):
Multiple biosimilar entrants and shifting payer preferences typically set the scene for further price erosion. Innovative value-based arrangements may also influence reductions. Over time, prices may stabilize in a range of $10,000–$25,000, aligning with biosimilar market tiers and increased competition.
Impact of Policy and Innovation
Ongoing policy reforms targeting drug pricing—such as Medicare negotiations, importation strategies, and increased transparency—could accelerate price reductions irrespective of patent timelines. Moreover, advancements in biosimilar development and increased clinician acceptance will likely heighten competitive pressures.
Conclusion
NDC 63402-0202 operates within a complex and evolving pharmaceutical environment. Its initial phase is characterized by premium pricing driven by clinical exclusivity and high development costs. Over the next five years, patent protections and regulatory landscapes will substantially influence pricing, with potential reductions tied to biosimilar competition and policy reforms. Stakeholders should monitor patent statuses, regulatory changes, and market adoption trends to refine revenue forecasts continually.
Key Takeaways
- The drug benefits from high initial pricing due to exclusivity and therapeutic value but faces imminent pricing pressure from biosimilar competitors.
- Short-term prices are projected between $40,000 and $80,000 annually per patient; long-term prices could decline to $10,000–$25,000.
- Patent expiry and regulatory developments are primary drivers of future price dynamics.
- Market demand depends significantly on the indication, prevalence, and payer acceptance, influencing revenue potential.
- Policy initiatives and innovation will accelerate or slow price adjustments, impacting overall market attractiveness.
FAQs
1. What factors influence the price of drugs like NDC 63402-0202?
Multiple factors, including patent status, manufacturing complexity, therapeutic value, competition, payer negotiations, and regulatory policies, determine drug pricing. High-value, patent-protected biologics tend to command premium prices, while biosimilar competition and policy reforms exert downward pressure.
2. How soon could biosimilars impact the pricing of this drug?
Biosimilars can enter markets typically 10-12 years post-original patent, but legal challenges and regulatory pathways may accelerate or delay entry. Once introduced, biosimilars can reduce prices by 20-50%, depending on market acceptance.
3. What is the typical price range for similar biologics?
Similar biologic therapies often range from $30,000 to $70,000 annually per patient, with some specialty drugs exceeding $100,000. The exact price depends on the indication, efficacy, and negotiated reimbursements.
4. How do policy changes influence future pricing projections?
Policy initiatives such as drug price negotiations, importation, and transparency measures tend to push prices downward, especially affecting drugs with upcoming patent expiries or biosimilar competition. Outcomes depend on legislative developments and market responses.
5. What should stakeholders monitor to anticipate price changes?
Regularly track patent statuses, regulatory approvals, biosimilar filings, payer reimbursement policies, and market adoption rates to stay informed about pricing trajectories and market dynamics.
Sources
[1] U.S. Food & Drug Administration (FDA) Databases
[2] IQVIA Institute Reports
[3] Sector-specific Market Intelligence Reports (Drug Pricing Strategies)
[4] Industry publications on Biosimilar Development and Market Trends
More… ↓
